2025
Intercontinental variations in the presentation and management of venous thromboembolism
Chaar C, Chan S, Lee A, Bikdeli B, Tiberio G, Chopard R, Weinberg I, Yamashita Y, Nikandish R, Monreal M. Intercontinental variations in the presentation and management of venous thromboembolism. JVS-Vascular Insights 2025, 3: 100201. DOI: 10.1016/j.jvsvi.2025.100201.Peer-Reviewed Original ResearchManagement of venous thromboembolismVenous thromboembolismPulmonary embolismLow-risk pulmonary embolismTreatment modalities of patientsOpen pulmonary embolectomyVenous thromboembolism presentationHigh-risk PEIntermediate-risk PELow-molecular-weight heparinLower body mass indexVitamin K antagonistsSystemic thrombolytic therapyProportion of patientsVenous thromboembolism patientsBody mass indexCoronary artery diseaseTreatment of PEPulmonary embolectomyK antagonistsOral anticoagulantsProximal DVTActive cancerOutpatient anticoagulationEndovascular treatment
2015
Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
Stutsky M, Reardon D, Lee A. Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood 2015, 126: 3275. DOI: 10.1182/blood.v126.23.3275.3275.Peer-Reviewed Original ResearchAnti-Xa levelsAnti-Xa monitoringLMWH doseLow molecular weight heparin therapyAbnormal body mass indexActions of providersWeight heparin therapyAcute kidney injuryChronic kidney diseaseHigh-risk patientsRetrospective chart reviewLong-term therapyBody mass indexClinical practice patternsFactor Xa inhibitorsNon-therapeutic levelsEnoxaparin doseHematology consultHeparin regimensTherapeutic LMWHHeparin therapyKidney injuryLMWH therapyRenal dysfunctionVenous thromboembolism
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply